On November 1, 2022, ZJKB Medical Device Technology Corporation issued an announcement. On October 28, 2022, the company's innovative product in the field of combination of medicine and machinery, disposable endoscope atomized microcatheter, was officially approved for listing by the China Drug Administration.
This product is the only aerosol microcatheter approved in China up to now. It has a number of patented technologies and has a wide range of indications. It can adapt to a variety of drugs and open up a wide range of application scenarios of combination of medicine and machinery in the field of lung disease treatment.
This product is used together with the endoscope, and under the guidance of the navigation system, it can accurately reach the lesions, and is used for irrigation, spraying medicine or using with contrast agents.
The patented microchannel chip at the tip of the atomized microcatheter and high-pressure infusion can reduce the drug particle size to 20 microns（μm) The drug can directly contact with the local lesions, and the distribution is more uniform, so that the local drug concentration is significantly increased, which can directly enhance the therapeutic effect.
The catheter body is made of safe materials with high drug compatibility, which can adapt to a variety of drugs. Its blunt round design at the front allows doctors to push smoothly during operation and protect the bronchial tube wall, reducing the risk of tissue damage.
The announcement said that the company has been deeply engaged in the interventional treatment of lung diseases for many years, and the atomized microcatheter is its first achievement in the field of combination of medicine and machinery. In the future, the company will cooperate with clinical experts and biopharmaceutical enterprises to explore the application of atomized microcatheter in bronchoscopic surgery anesthesia, tuberculosis treatment, targeted drug delivery of tumor drugs, etc., and continue to expand its use scenarios to cover a wider range of lung disease treatment, Consolidate the company's leading edge in the field of precise intervention diagnosis and treatment of lung diseases.